Novo Nordisk has agreed to pay up to $2.6 billion to license an experimental, weekly weight-loss pill from China's Hengrui Pharma, according to The Financial Times. The deal is the Danish company's second licensing move since its investor day last week, where pledges to reignite growth with new drugs failed to persuade investors.

The Hengrun arrangement signals how Novo intends to defend its position in the oral obesity segment, where it is trying to regain ground lost to Eli Lilly. A weekly oral therapy would be a significant entrant to the market, analysts said, because current pill regimens impose daily dosing burdens that affect adherence.

The deal follows Novo's agreement last week to license technology from Nanexa that could extend injection intervals to one weight-loss shot every few months. Together, the two transactions sketch a portfolio strategy built on dosing convenience rather than new mechanisms alone.

For R&D managers tracking the obesity pipeline, the licensing route carries a clear trade-off: Novo is buying clinical-stage assets with milestone-heavy deal structures — the Hengrui payment reaches $2.6 billion only if development and commercialization milestones are met — rather than absorbing the full risk of internal discovery. The financial terms beyond the headline figure, including any upfront payment, were not disclosed in the report.

Roche drops emugrobart after data review

The same morning brought a counterpoint on pipeline discipline. Roche halted development of one of its obesity drug candidates after clinical-trial data suggested the medicine, emugrobart, did not hit internal targets, The Wall Street Journal reports.

Roche returned rights to the drug to Chugai Pharmaceutical, the Japanese company it largely owns and which originally discovered the molecule before licensing it to Roche. The decision retires an asset Roche had previously estimated could reach annual peak sales of between $1.21 billion and $2.41 billion.

The termination does not empty Roche's obesity portfolio. The company is developing two obesity injections and one pill, and sees potential for each of them to exceed $3.6 billion in peak sales. Those projections remain vendor estimates, not measured clinical results, and each program still faces the trial outcomes that ended emugrobart's run.

Both moves land in a market where Novo and Eli Lilly are racing to move beyond injectable GLP-1 therapies, and where Chinese-origin molecules are becoming in-licensing targets for Western pharma. Novo has now committed to two externally sourced technologies within a week, while Roche has demonstrated it will cut a sub-scale asset even in a high-value indication.

What remains to be seen is whether Hengrui's weekly pill can deliver clinical data that justifies the milestone structure — and whether Roche's remaining trio of obesity candidates clears the internal performance bar that emugrobart missed.